Accretion Pharmaceuticals (NSE:ACCPL) ROCE %: 27.66% (As of Mar. 2026)


NSE:ACCPL Accretion Pharmaceuticals Ltd NSE:ACCPL
18 GF Score
Price ₹149.15
! 5 Warning Signs
View Full Analysis

What is Accretion Pharmaceuticals ROCE %?

Accretion Pharmaceuticals NSE:ACCPL -1.81% 18 ROCE % is 27.66% as of Mar. 2026. GuruFocus rates NSE:ACCPL with a GF Score™ of 18/100. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Accretion Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was 27.66%.

Accretion Pharmaceuticals  (NSE:ACCPL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Accretion Pharmaceuticals ROCE % Related Terms

Accretion Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Accretion Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accretion Pharmaceuticals ROCE % Chart

Accretion Pharmaceuticals Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
18.33 18.24 71.32 90.45 24.95

Accretion Pharmaceuticals Semi-Annual Data
Mar22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
ROCE % Get a 7-Day Free Trial 0.00 64.40 0.00 28.52 27.66
NSE:ACCPL
18GF Score
Accretion Pharmaceuticals Ltd NSE:ACCPL
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Accretion Pharmaceuticals ROCE % Calculation

Accretion Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=139.31/( ( (0 - 0) + (766.555 - 208.121) )/ 1 )
=139.31/( (0+558.434)/ 1 )
=139.31/558.434
=24.95 %

Accretion Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=142.99/( ( (590.747 - 115.118) + (766.555 - 208.121) )/ 2 )
=142.99/( ( 475.629 + 558.434 )/ 2 )
=142.99/517.0315
=27.66 %

(1) Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 27.66% mean?
Accretion Pharmaceuticals (NSE:ACCPL) has a ROCE % of 27.66% as of Mar. 2026.
Is Accretion Pharmaceuticals' ROCE % too high?
Accretion Pharmaceuticals' current ROCE % is 27.66%. The Drug Manufacturers industry median ROCE % is 7.00. Accretion Pharmaceuticals' value of 27.66% is 295.4% above this industry median. Overall, Accretion Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' ROCE % compare to LLY and JNJ?
Accretion Pharmaceuticals' ROCE % of 27.66% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Accretion Pharmaceuticals' value of 27.66% is 295.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Pharmaceuticals's current ROCE % of 27.66% is 295.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Pharmaceuticals's current ROCE % is 27.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current ROCE % of 27.66%. The current ROCE % is 27.66% and 295.4% above the Drug Manufacturers industry median of 7.00. Accretion Pharmaceuticals' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current ROCE % is 27.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Accretion Pharmaceuticals Business Description

Address 29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, Vasna-Chacharwadi, Ta - Sanand District, Ahmedabad, GJ, IND, 382213
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
18GF Score

Get the complete analysis for NSE:ACCPL

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹149.15
Price